Payer Intelligence Briefing · Market Access & Reimbursement · GLP-1
GLP-1 Payer Insights 2026 Strategic Briefing: A Cross-System Pricing & Reimbursement Analysis of UK and US Market Access
A like-for-like comparison of how the UK NICE-NHS and US Medicaid MCO systems answer the same strategic questions on GLP-1 reimbursement, built on real-world qualitative interviews with senior Payers.
Complimentary access. Instant download.
What the Research Reveals
Two systems, one structural problem
- The pay-now-benefit-later mismatch is structural in both systems. The entity paying for the GLP-1 today is not the entity that captures the long-horizon cost offset.
- Adherence assumptions are weak in both systems. Real-world persistence at 12 months sits below 40%, but neither system formally re-baselines cost-effectiveness against it.
- Cardiometabolic is the rationale, but obesity is the demand driver. Funding rests on the cardiovascular case while obesity demand pulls utilization upward.
- Manufacturer rebates. A separate clinical-economic gate in the UK; a direct determinant of formulary placement in the US.
- Implementation horizon. A 90-day legal mandate in the UK; no equivalent trigger in the US.
- Competitive lens. The US reframes GLP-1 coverage as a member-acquisition and retention lever. The UK has no equivalent logic.
Report overview
The GLP-1 receptor agonist class has become one of the most commercially significant therapeutic categories of the decade. The 2024 cardiovascular indication expansion unlocked new payer pathways and is reshaping access economics in both the UK and US. Yet the reimbursement reality on the ground, captured here in Omnitheia’s primary research, reveals a structural mismatch between published cost-effectiveness narratives and operational budget reality.
This report synthesizes senior UK and US payer testimony, gathered under matched discussion guides, into a single cross-system comparison. The findings carry direct implications for sponsors with cardiometabolic assets, for investors weighing exposure, for business-development teams evaluating licensing, and for the consulting and valuation firms supporting transactions in the class.
Scope
Geographies:
Therapy area:
Reimbursement architectures:
Reimbursement criteria:
What UK and US payers require now to fund GLP-1s, and the evidence they want next, set out for each system and then compared.
Cross-system synthesis:
A flowing analysis of the strategic payer questions, from decision authority and the SELECT trial through adherence, value-based contracting, oral formulations, and the 24-month outlook.
Verbatim evidence:
Curated UK and US quotes organized by theme, presented in parallel.
Stakeholder translation:
Actionable insight split into two tracks, one for companies working with GLP-1 pipeline, one for investors and licensing teams.
How Industry Leaders Are Using This Report
Pharma, Biotech, and Market-Access Teams
For teams positioning a cardiometabolic asset, the report gives the payer benchmarks that decide whether coverage follows approval. It shows where the access decision has moved, which evidence payers reward, and which objections to expect in negotiation.
› Plan engagement where coverage is actually decided. A national yes from NICE or a P&T committee is necessary but not sufficient, because both systems now devolve the operational call to a local layer. The report shows where to direct access effort instead.
› Design trial endpoints that clear legacy obesity exclusions. Both systems relied on cardiovascular outcomes to fund what would otherwise be restricted as weight-loss. The report sets out the cardiovascular, renal, and metabolic endpoints that matter.
› Position an oral asset on the value payers actually reward. UK commissioners will accept slightly lower efficacy for a materially cheaper, simpler-to-supply product. The report explains why cost-saving substitution, not efficacy parity, is the credible claim.
› Build the adherence evidence neither system currently has. Real-world persistence sits below 40 percent at 12 months while forecasts assume far higher. The report identifies the persistence data that carries the most weight with payers in both markets.
Business Development, Licensing, and Investment Teams
For teams pricing a deal or defending a valuation, the report translates payer behaviour into the assumptions that drive a forecast. It sets out which assumptions are inflating GLP-1 economics and which commercial terms payers will and will not accept.
› Counter the plan-churn objection in negotiation. The claim that US plans avoid long-horizon therapies because members switch plans is contradicted by payer testimony: plans use coverage to win and hold members. The report gives you the evidence to hold valuation.
› Build a defensible adherence assumption into forecasts. With real-world persistence running at roughly half the rate most forecasts assume, the report sets out the downside adjustment to apply to peak-sales models.
› Structure deals around terms payers accept. Both UK and US payers prefer flat net discounts over complex outcomes contracts, which the UK described as logistically unmanageable. The report sets out what to propose and what to avoid.
› Factor cardiovascular & other cardiometabolic indications into asset value. A credible cardiovascular or a broader cardiometabolic development plan materially improves access prospects compared with a weight-loss-only profile. The report explains why obesity-only valuations undervalue it.
Access Pathways: Drugs Highlighted by Payers
- Semaglutide (Ozempic, Wegovy, Rybelsus): the Wegovy MACE indication (March 2024, post-SELECT) is the cardiovascular wedge that opened restricted obesity coverage.
- Tirzepatide (Mounjaro, Zepbound): the UK weight-management pathway where NHS England layered BMI 40+ and 4-of-5-conditions restrictions onto the NICE recommendation.
- Retatrutide and the triple-agonist pipeline: the next wave across cardiometabolic, NASH/MASH, and OSA indications.
- Oral GLP-1 pipeline (Rybelsus in market; Pfizer and Lilly candidates): positioned on cost (UK) and tolerability (US), not access expansion.
Table of Contents
- 1.0 Executive Summary
- 2.0 Market Analysis and Trends
- 2.1 Market Potential, the GLP-1 Class Today
- 2.2 Reimbursement Potential, UK and US Architectures
- 2.3 Key Market Dynamics
- 3.0 Key Reimbursement Criteria
- 3.1 UK Reimbursement Criteria, Current
- 3.2 UK Reimbursement Criteria, Near Future
- 3.3 US Reimbursement Criteria, Current
- 3.4 US Reimbursement Criteria, Near Future
- 3.5 Cross-System Convergences and Divergences
- 4.0 Verbatim Q&A Comparison: UK and US Payer Perspectives
- 5.0 Cross-System Verbatim Payer Quotes
- 6.0 Key Insights for Stakeholders
- 6.1 Companies Working with GLP-1 Pipeline
- 6.2 Investors and Licensing Teams
- 7.0 Themes, Hypotheses and Conclusions
- 7.1 Cross-System Themes
- 7.2 Strategic Hypotheses
- 7.3 Conclusions
Report overview
Scope
Geographies:
Therapy area:
Reimbursement architectures:
Reimbursement criteria:
What UK and US payers require now to fund GLP-1s, and the evidence they want next, set out for each system and then compared.
Cross-system synthesis:
A flowing analysis of the strategic payer questions, from decision authority and the SELECT trial through adherence, value-based contracting, oral formulations, and the 24-month outlook.
Verbatim evidence:
Curated UK and US quotes organized by theme, presented in parallel.
Stakeholder translation:
Actionable insight split into two tracks, one for companies working with GLP-1 pipeline, one for investors and licensing teams.
Table of Contents
The Drugs at the Center of This Analysis
Semaglutide (Ozempic, Wegovy, Rybelsus)
The Wegovy MACE indication (March 2024, post-SELECT) is the cardiovascular wedge that opened restricted obesity coverage.
Tirzepatide (Mounjaro, Zepbound)
The UK weight-management pathway where NHS England layered BMI 40+ and 4-of-5-conditions restrictions onto the NICE recommendation.
Retatrutide and the triple-agonist pipeline
The next wave across cardiometabolic, NASH/MASH, and OSA indications.
Oral GLP-1 pipeline (Rybelsus in market; Pfizer and Lilly candidates)
Positioned on cost (UK) and tolerability (US), not access expansion.